Please login to the form below
medicines access
This page shows the latest medicines access news and features for those working in and with pharma, biotech and healthcare.
MPs threaten to publish Vertex’s Orkambi price if no deal struck
Confidential price discounts have become a routine part of the NICE and NHS England processes of granting market access in the country, and the committee’s move could undermine the wider ... The company simply says that it “welcomes the Committee's
Latest news
-
US pricing plan slammed for imposing “foreign price controls”
President Trump’s latest plan to bring down the cost of medicines in the US has drawn fire from the drug industry, which claims it will undermine access to medicines for ... foreign price controls from countries with socialised health care systems that
-
EMA to review Bluebird’s blood disorder gene therapy
Bluebird Bio announced late last week that the European Medicines Agency has accepted its gene therapy LentiGlobin for accelerated review. ... LentiGlobin is already part of the EMA’s Adaptive Pathways pilot programme, which aims to improve timely
-
GSK to reverse ‘no KOL’ policy, admitting it has hit marketing
It concluded: “We believe this has led to a reduced understanding of our products and is, ultimately, restricting patients’access to truly innovative medicines and vaccines.”. ... We will do more to help HCPs improve their knowledge of the
-
AstraZeneca chief on Brexit: “it’s going to be really painful”
Soriot also claims to be lowest paid CEO in sector. AstraZeneca’s stockpiling of medicines ahead of Brexit is a temporary safeguard at best, and shortages could follow if no customs ... Too much friction in that process could affect patients’ability
-
Labour party divided on Brexit ‘People’s Vote’
Against this background, pharma companies are now investing time and money into ‘no deal’Brexit planning, including stockpiling medicines. ... Even though we very much appreciate the science and capabilities in the UK, it is not possible to
More from news
Approximately 4 fully matching, plus 447 partially matching documents found.
Latest Intelligence
-
Brexit: can pharma ‘take back control’ of the narrative?
As such, many companies have been planning for a hard Brexit, taking steps to ensure that the infrastructure is in place to avoid any disruption to patient access to medicines. ... For example the sector has continued to see UK patients gaining slower
-
The case for a second Brexit referendum: “We need the informed consent of the people”
As many in the pharma industry know, the EEA allows Norway, Iceland and Liechtenstein to be part of the EMA and gain access to the new medicines at the same time. ... May and her cabinet looked to address concerns about medicines access in the Chequers
-
China: AstraZeneca’s new engine for growth and innovation
Despite our success in partnering with hospitals and government to improve access to new medicines, there remains a significant unmet medical need across China. ... Economic growth has enabled people to pay out-of-pocket, with regions and cities now
-
Stakeholder dialogue in Europe’s adaptive pathways pilot
The European Medicines Agency (EMA) has worked for several years to speed patient access to new medicines. ... Evidence suggests that medicines using the resulting accelerated access initiatives experience variable reimbursement outcomes due to
-
The European Medicines Agency: PRIME’d for access?
The European Medicines Agency: PRIME’ d for access? Leela Barham examines the impact of the EMA's PRIME fast track system after two years. ... Regulators around the world have been working for decades to speed up access to the best of the new medicines
More from intelligence
Approximately 0 fully matching, plus 80 partially matching documents found.
Latest appointments
-
Pfizer’s Alan Maine moves to Edelman
Maine, who previously served as head of policy and public affairs at Pfizer UK, was responsible for government affairs and market access policy development activity, covering both corporate and therapy area ... During his time at Pfizer, Maine also
-
Sobi names Holly May VP of sales and marketing, US
May’s new role will see her lead the biopharma’s commercial team in bringing Sobi ’s medicines to the country. ... She will also collaborate with the operations and patient access team to ensure the medicines are accessible to as many appropriate
-
Inceptua Medicines Access appoints senior new-hires
Inceptua Medicines Access appoints senior new-hires. The new speciality business unit appoints senior project manager and office manager. ... Multipharma’s new speciality business unit, Inceptua has appointed Ruth Rostron as its new senior project
-
Multipharma launches Inceptua Medicines Access
Multipharma launches Inceptua Medicines Access. The group will be split into three sub-divisions. ... Multipharma has launched Inceptua Medicines Access, a speciality business unit that offers access to pre-approval and unlicensed medicines.
-
Sandoz UK promotes Tim de Gavre to country head
As a company, Sandoz has an exciting portfolio of medicines and future product pipeline. ... I look forward to working with the Sandoz team, and in partnership with the NHS to help patients access these important medicines.”.
More from appointments
Approximately 0 fully matching, plus 20 partially matching documents found.
Latest from PMHub
-
New opportunities in emerging markets
This growth is set to continue. In parallel, we are seeing an increased focus among emerging market governments on public healthcare reform: expanding their populations’ access to medicines by establishing universal ... Greater purchasing power and
-
Unique forum will unite NHS and industry to drive innovation
Unique forum will unite NHS and industry to drive innovation. HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at ... The event aims to help industry develop stronger
-
OPEN Access Consulting
OPEN Access Consulting. OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. ... High-cost medicines. Rare diseases. Long-term conditions. Generic and biosimilar introduction &defence.
-
Accession
A passion to harness the power of market access to ensure patients gain access to life changing medicines and devices. ... The early industry pioneers of market access, are the creative force behind Accession.
-
Four Health Communications
Patient Access. We see patient access to medicines as the critical challenge in today’ s pharma market environment. ... challenges. We work with our clients in a variety of ways to generate real-life insight into the issues being encountered by
More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.
Featured jobs
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Business Development Director – Health Education
-
excellent commission
-
Systematic Reviewer - Oxford
-
Negotiable
-
Senior Account Manager
-
Competitive Salary Offered
- Account Executive/ Senior Account Executive
-
competitive Salary Offfered
-
Account Manager / Account Director
-
Competative
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Account Director
-
Competitive Salary Offered
- Account Manager- Healthcare Advertising
-
Negotiable
-
Associate Director
-
£75, 000-90, 000
- Senior Account Executive with progression to Account Manager, Me...
-
Excellent package
-
Medical Writer
-
Bonus Scheme, PTO &Private Healthcare
-
Experienced Medical Writers
-
Competitive Salary and Benefits
-
Business Director
-
Competitive Salary Offered
Subscribe to our email news alerts
- Industry frustrated by late warning on 'no deal' Brexit disruption
- UK’s genomics leadership attracts IQVIA investment, regardless of Brexit
- Lucid Group celebrate another magical year at their Winter Meeting
- Biogen picks up another drug from wide-ranging Ionis alliance
- As France protests, Sanofi takes axe to 670 jobs
- Leicester NHS Trust’s staff intranet is integral to HCPs’ working day
PMHub
M&F Health
M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...
Latest intelligence
- Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
- What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
- What everyone forgets about good organisational change in pharma
- Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
- Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
- Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...
Quick links
Infographics
